Table 2.
Efficacy of insulin degludec 100 U/mL versus glargine insulin on HbA1c and fasting blood glucose in patients with type 2 diabetes mellitus
| Study | Arm | HbA1c (% ± SD) | HbA1c reduction (% ± SD) | ETD (%) for HbA1c reduction (CI 95%) | FBG (mmol/L±SD) | FBG reduction (mmol/L) | ETD (mmol/L) for FPG [CI 95%] |
|---|---|---|---|---|---|---|---|
| BEGIN Once Long13 | IDeg (n=773) | 7.1 | −1.06 (±1.01) | 0.09 [−0.04, 0.22] | 5.9 | −3.8±3.04 | −0.43 [−0.74, −0.13] |
| IGla (n=257) | 7.0 | −1.19 (±0.97) | P = NA | 6.4 | −3.3±2.87 | P=0.005 | |
| BEGIN Once Long (extension)14 | IDeg (n=773) | 7.0±0.9 | NA | 0.07 [−0.07, 0.22] | 5.56±1.82 | −4.17 | −0.36 [−0.67, −0.05] |
| IGla (n=257) | 6.9±0.8 | NA | P=0.339 | 5.93±1.69 | −3.56 | P=0.021 | |
| BEGIN Once Asia15 | IDeg (n=289) | 7.2 | −1.24 | 0.11 [−0.03, 0.24] | 5.5 | 2.88 | −0.09a [−0.41, 0.23] |
| IGla (n=146) | 7.1 | −1.35 | P = NA | 5.7 | 2.97 | P=0.59 | |
| BEGIN Basal-Bolus Type 216 | IDeg (n=744) | NA | −1.10 | NA | −2.3 | −0.29 [−0.65, 0.06] | |
| IGla (n=248) | NA | −1.18 | 0.08 [−0.05, 0.21] P = NA |
NA | −2.0 | P=0.1075 | |
| IDeg (n=226) | NA | −1.07 | IDegForced-Flex versus IDeg NA |
5.8 | NA | IDegForced-Flex versus IDeg −0.05 [0.45, 0.25] P = NA |
|
| BEGIN Flex T217 | IDegForced-Flex (n=230) | NA | −1.28 | IDegForced-Flex versus IGla 0.04 [−0.12, 0.20] |
5.8 | NA | IDegForced-Flex versus IGla −0.42 [−0.82, −0.02] |
| IGla (n=229) | NA | −1.26 | 6.2 | NA | P=0.04 |
Note:
a
ETD (mmol/L) for FPG in favor of IGla, mean ± SD.
Abbreviations: CI, confidence interval; ETD, estimated treatment difference; FPG, fasting plasma glucose; IDeg, insulin degludec; IDegForced-Flex, insulin degludec with forced flexible scheme; IDet, detemir insulin; IGla, glargine insulin; NA, not available; SD, standard deviation.